- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- EXPD-101/FXS7553 Dose 1, EXPD-101/FXS7553 Dose 2, Placebo
- Drug
- Lead sponsor
- Expedition Therapeutics, Inc
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Encino, California • Northridge, California + 26 more
Location Directory
Clinical trials in Columbus, Ohio
This page shows live ClinicalTrials.gov search results for Columbus, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
10849
Shown on this page
12
Current sort
Recently updated
Location scope
Columbus, OH
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 289–300 of 10,849 matching trials in Columbus, OH.
Live ClinicalTrials.gov results.
Institutions in Columbus
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- INS1201
- Genetic
- Lead sponsor
- Insmed Gene Therapy LLC
- Industry
- Eligibility
- 2 Years to 4 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Davis, California • Los Angeles, California + 7 more
- Conditions
- Acute Kidney Injury, Fluid Overload, Prematurity Complications, Risk Factors, Epidemiology, Chronic Kidney Disease(CKD), Hypertension
- Interventions
- Not listed
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 0 Minutes to 2 Weeks
- Enrollment
- 8,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 48 more
- Conditions
- Huntington Disease
- Interventions
- Pridopidine, Placebo
- Drug
- Lead sponsor
- Prilenia
- Industry
- Eligibility
- 23 Years to 65 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 21 more
- Conditions
- Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Carvedilol, Laboratory Biomarker Analysis, Patient Observation
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 491 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2031
- U.S. locations
- 577
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Hot Springs, Arkansas + 375 more
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- BI 764198, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 77
- States / cities
- Alabaster, Alabama • Huntsville, Alabama • Surprise, Arizona + 66 more
- Conditions
- Meningioma
- Interventions
- Zanzalintinib
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 17 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Nivolumab, Relatlimab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Columbus, Ohio
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Gilteritinib, Venetoclax
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 226
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 179 more
- Conditions
- Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
- Interventions
- Cyclophosphamide, Daratumumab, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Prednisone, Vincristine, Vincristine Sulfate
- Drug · Biological
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 9
- States / cities
- Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 6 more
- Conditions
- Endometriosis
- Interventions
- Observational study, no intervention
- Other
- Lead sponsor
- Aspira Women's Health
- Industry
- Eligibility
- 14 Years to 50 Years · Female only
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 10
- States / cities
- Chandler, Arizona • Burbank, California • Newark, Delaware + 7 more
- Conditions
- Ampulla of Vater Carcinoma, Appendix Carcinoma, Carcinoma of Unknown Primary With Gastrointestinal Profile, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Malignant Digestive System Neoplasm, Rectal Carcinoma, Small Intestinal Carcinoma
- Interventions
- PAGODA algorithm, Oxaliplatin, Folinic Acid, Fluorouracil
- Other · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 360
- States / cities
- Fairbanks, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 268 more